Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

New Antibiotic Treatment Options for Uncomplicated Anogenital Gonorrhoea Infections - a Double-blind Randomized Controlled Non-inferiority Trial

Trial Profile

New Antibiotic Treatment Options for Uncomplicated Anogenital Gonorrhoea Infections - a Double-blind Randomized Controlled Non-inferiority Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ertapenem (Primary) ; Fosfomycin (Primary) ; Gentamicin (Primary) ; Ceftriaxone
  • Indications Gonorrhoea
  • Focus Therapeutic Use
  • Acronyms NABOGO
  • Most Recent Events

    • 01 Jun 2023 Results of secondary analysis (n=221) assessing the spontaneous clearance among patients with asymptomatic anal, pharyngeal, vaginal and urethral NG infections and the determinants associated with spontaneous clearance, participants from NABOGO trial, published in the Sexually Transmitted Infections.
    • 01 May 2022 Primary endpoint (Proportion of participants with treatment success in each study arm for the included anatomic infection for fosfomycin arm/group) has not been met as per results published in The Lancet Infectious Diseases
    • 01 May 2022 Primary endpoint (Proportion of participants with treatment success in each study arm for the included anatomic infection for Gentamicin arm/group) has not been met as per results published in The Lancet Infectious Diseases
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top